Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus

B Raman, DA Bluemke, TF Lüscher… - European heart …, 2022‏ - academic.oup.com
Emerging as a new epidemic, long COVID or post-acute sequelae of coronavirus disease
2019 (COVID-19), a condition characterized by the persistence of COVID-19 symptoms …

COVID-19 therapeutics: Challenges and directions for the future

PC Robinson, DFL Liew, HL Tanner… - Proceedings of the …, 2022‏ - pnas.org
The emergence of SARS-CoV-2 triggering the COVID-19 pandemic ranks as arguably the
greatest medical emergency of the last century. COVID-19 has highlighted health disparities …

Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with …

AC Spyropoulos, M Goldin, D Giannis… - JAMA internal …, 2021‏ - jamanetwork.com
Importance Hospitalized patients with COVID-19 are at risk for venous and arterial
thromboembolism and death. Optimal thromboprophylaxis dosing in high-risk patients is …

Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19

ATTACC, ACTIV-4a, and REMAP-CAP … - New England Journal …, 2021‏ - Mass Medical Soc
Background Thrombosis and inflammation may contribute to the risk of death and
complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized …

Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial

S Ehrmann, J Li, M Ibarra-Estrada, Y Perez… - The Lancet …, 2021‏ - thelancet.com
Background Awake prone positioning has been reported to improve oxygenation for patients
with COVID-19 in retrospective and observational studies, but whether it improves patient …

[HTML][HTML] Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre …

E Ramacciotti, LB Agati, D Calderaro, VCR Aguiar… - The Lancet, 2022‏ - thelancet.com
Background Patients hospitalised with COVID-19 are at risk for thrombotic events after
discharge; the role of extended thromboprophylaxis in this population is unknown. Methods …

[HTML][HTML] ISTH guidelines for antithrombotic treatment in COVID‐19

S Schulman, M Sholzberg, AC Spyropoulos… - Journal of Thrombosis …, 2022‏ - Elsevier
Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with
coronavirus disease 2019 (COVID‐19) may realize additional benefits from heparins …

Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial

JM Connors, MM Brooks, FC Sciurba, JA Krishnan… - Jama, 2021‏ - jamanetwork.com
Importance Acutely ill inpatients with COVID-19 typically receive antithrombotic therapy,
although the risks and benefits of this intervention among outpatients with COVID-19 have …